23rd EHA Congress
Fusion Pharma will present interim results of the ongoing Phase ½ clinical study of PF-114 in CML patients at the 23rd congress of European Hematology Association (EHA) in Stockholm, June 14−17, 2018.
In addition to the congress program Fusion Pharma plans to conduct a scientific advisory board meeting devoted to the current status and future plans of PF-114 development.

Submitted abstract of PF-114 presentation at EHA.
Made on